EQ · Equillium, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on EQ. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About EQ · Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Live Quote
HOLD (score +3) · 12-1 mom 513.9% · RSI 54.9 · above_both · -10.4% from high
Targets blend Wall Street consensus (8 analysts: low $4.00 / mean $7.13 / high $12.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Equillium (EQ) is a clinical-stage biotech with two pipeline assets: EQ504 (novel AhR modulator entering Phase 1 for UC in mid-2026) and EQ302 (IL-15/IL-21 inhibitor in preclinical for celiac disease). The stock has run from ~$0.84 to $2.90 over the past year (+98%), now near its 52-week high of $3.10. Seven Form 4s were filed in the last 14 days as flagged, but inspection reveals these are overwhelmingly routine option vesting events (code M = exercise) with subsequent Rule 10b5-1 sales — not open-market discretionary purchases. Christine Zedelmayer exercised multiple tranches then sold via a pre-scheduled plan; Penny Tom did the same. The five directors who received options grants (Bradbury, Demski, Pruzanski, McDermott, Steel) are standard annual compensation awards (code A). There is no genuine open-market buy (P code) from any insider in the 90-day window. With the stock at/near its high, IV elevated (~160-174% ATM), and no price dislocations identified, this does not support a mispriced setup — it is a pre-revenue biotech with binary clinical risk ahead of Phase 1 initiation.
Lessons Referencing This Ticker
In low-float, high-short-interest commodity names (~10%+ shorts), pre-earnings positioning can cause large directional spikes (10-15%) that distort entry pricing and skew readings. These spikes are driven by gamma positioning and short-covering, not fundamental information. Enter spreads AFTER the pre-event spike resolves, not before.
extracted Jun 19, 2026 from 2026-06-01-UEC-earnings-put-spread
In cybersecurity names during AI-capex peaks, executive sales (even Rule 10b5-1) at prices significantly below current spot should be weighted more heavily than analyst upgrades. Insiders are closer to the data and may be positioning for a plateau.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call
RSI(14) > 80 is a valid overbought signal that should reduce the technical_was_useful score and trigger a mean-reversion warning. In the scoring methodology, technical signals should not be dismissed as 'Tier 3 confirmation' when they indicate extreme conditions.
extracted Jun 19, 2026 from 2026-06-01-PANW-earnings-debit-call